Dupilumab for prurigo nodularis: long-term effects
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This study follows people with moderate-to-severe prurigo nodularis who are starting dupilumab. It looks at how the medicine works over time and how it affects the immune system, to help understand long-term benefits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have moderate-to-severe prurigo nodularis (itchy, bumpy skin condition).
- You are starting treatment with dupilumab (a medication).
- You agree to be part of the BioDay registry (a research database).
- If you are asked to give extra blood or skin samples for research, you agree to join the UMC Utrecht Biobank.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called ICP-332 for people with prurigo nodularis (a condition causing very itchy, hard bumps on the skin). It aims to see if the drug can safely reduce itching and improve skin lesions.
This study tests a drug called lebrikizumab for people with severe prurigo nodularis, a condition with very itchy skin bumps. The drug is given as an injection and aims to reduce itching and clear the bumps faster.
This trial looks at how the immune system reacts in people with nasal polyps. It may help doctors better understand and treat this condition.
This study tests whether the medication dupilumab can safely reduce itching and skin bumps in children aged 6 months to under 18 years who have prurigo nodularis, a skin condition that causes intense itching and nodules. Participation involves taking the study drug and tracking itch daily.
This study looks at how well nemolizumab works in real-world settings for adults with moderate-to-severe prurigo nodularis, a skin condition that causes intense itching and bumps. If you are starting this medication as part of your normal care, you may be able to join.
This study looks at how well dupilumab works for children and teens with severe eczema (atopic dermatitis) even when the rash is not widespread. It aims to see if the treatment helps with itching, quality of life, and rashes in visible or sensitive areas.
Hear when a new Prurigo Nodularis (PN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.